Gut microbiome and kidney disease: a bidirectional relationship

Souhaila M. Al Khodor, Ibrahim F. Shatat

Research output: Contribution to journalReview article

26 Citations (Scopus)

Abstract

Recent technological advances and efforts, including powerful metagenomic and metatranscriptomic analyses, have led to a tremendous growth in our understanding of microbial communities. Changes in microbial abundance or composition of human microbial communities impact human health or disease state. However, explorations into the mechanisms underlying host–microbe interactions in health and disease are still in their infancy. Although changes in the gut microbiota have been described in patients with kidney disease, the relationships between pathogenesis, mechanisms of disease progression, and the gut microbiome are still evolving. Here, we review changes in the host–microbiome symbiotic relationship in an attempt to explore the bidirectional relationship in which alterations in the microbiome affect kidney disease progression and how kidney disease may disrupt a balanced microbiome. We also discuss potential targeted interventions that may help re-establish this symbiosis and propose more effective ways to deploy traditional treatments in patients with kidney disease.

Original languageEnglish
Pages (from-to)921-931
Number of pages11
JournalPediatric Nephrology
Volume32
Issue number6
DOIs
Publication statusPublished - 1 Jun 2017

Fingerprint

Kidney Diseases
Microbiota
Disease Progression
Metagenomics
Symbiosis
Health
Gastrointestinal Microbiome
Growth
Therapeutics

Keywords

  • Acute kidney injury
  • Chronic kidney disease
  • Dysbiosis
  • End-stage renal disease
  • Hemodialysis
  • Hypertension
  • Microbiota
  • Peritoneal dialysis
  • Prebiotics
  • Probiotics
  • Transplantation

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Nephrology

Cite this

Gut microbiome and kidney disease : a bidirectional relationship. / Al Khodor, Souhaila M.; Shatat, Ibrahim F.

In: Pediatric Nephrology, Vol. 32, No. 6, 01.06.2017, p. 921-931.

Research output: Contribution to journalReview article

@article{174bcf3812fc40eca18916c14a2dd76b,
title = "Gut microbiome and kidney disease: a bidirectional relationship",
abstract = "Recent technological advances and efforts, including powerful metagenomic and metatranscriptomic analyses, have led to a tremendous growth in our understanding of microbial communities. Changes in microbial abundance or composition of human microbial communities impact human health or disease state. However, explorations into the mechanisms underlying host–microbe interactions in health and disease are still in their infancy. Although changes in the gut microbiota have been described in patients with kidney disease, the relationships between pathogenesis, mechanisms of disease progression, and the gut microbiome are still evolving. Here, we review changes in the host–microbiome symbiotic relationship in an attempt to explore the bidirectional relationship in which alterations in the microbiome affect kidney disease progression and how kidney disease may disrupt a balanced microbiome. We also discuss potential targeted interventions that may help re-establish this symbiosis and propose more effective ways to deploy traditional treatments in patients with kidney disease.",
keywords = "Acute kidney injury, Chronic kidney disease, Dysbiosis, End-stage renal disease, Hemodialysis, Hypertension, Microbiota, Peritoneal dialysis, Prebiotics, Probiotics, Transplantation",
author = "{Al Khodor}, {Souhaila M.} and Shatat, {Ibrahim F.}",
year = "2017",
month = "6",
day = "1",
doi = "10.1007/s00467-016-3392-7",
language = "English",
volume = "32",
pages = "921--931",
journal = "Pediatric Nephrology",
issn = "0931-041X",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Gut microbiome and kidney disease

T2 - a bidirectional relationship

AU - Al Khodor, Souhaila M.

AU - Shatat, Ibrahim F.

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Recent technological advances and efforts, including powerful metagenomic and metatranscriptomic analyses, have led to a tremendous growth in our understanding of microbial communities. Changes in microbial abundance or composition of human microbial communities impact human health or disease state. However, explorations into the mechanisms underlying host–microbe interactions in health and disease are still in their infancy. Although changes in the gut microbiota have been described in patients with kidney disease, the relationships between pathogenesis, mechanisms of disease progression, and the gut microbiome are still evolving. Here, we review changes in the host–microbiome symbiotic relationship in an attempt to explore the bidirectional relationship in which alterations in the microbiome affect kidney disease progression and how kidney disease may disrupt a balanced microbiome. We also discuss potential targeted interventions that may help re-establish this symbiosis and propose more effective ways to deploy traditional treatments in patients with kidney disease.

AB - Recent technological advances and efforts, including powerful metagenomic and metatranscriptomic analyses, have led to a tremendous growth in our understanding of microbial communities. Changes in microbial abundance or composition of human microbial communities impact human health or disease state. However, explorations into the mechanisms underlying host–microbe interactions in health and disease are still in their infancy. Although changes in the gut microbiota have been described in patients with kidney disease, the relationships between pathogenesis, mechanisms of disease progression, and the gut microbiome are still evolving. Here, we review changes in the host–microbiome symbiotic relationship in an attempt to explore the bidirectional relationship in which alterations in the microbiome affect kidney disease progression and how kidney disease may disrupt a balanced microbiome. We also discuss potential targeted interventions that may help re-establish this symbiosis and propose more effective ways to deploy traditional treatments in patients with kidney disease.

KW - Acute kidney injury

KW - Chronic kidney disease

KW - Dysbiosis

KW - End-stage renal disease

KW - Hemodialysis

KW - Hypertension

KW - Microbiota

KW - Peritoneal dialysis

KW - Prebiotics

KW - Probiotics

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=84964627195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964627195&partnerID=8YFLogxK

U2 - 10.1007/s00467-016-3392-7

DO - 10.1007/s00467-016-3392-7

M3 - Review article

C2 - 27129691

AN - SCOPUS:84964627195

VL - 32

SP - 921

EP - 931

JO - Pediatric Nephrology

JF - Pediatric Nephrology

SN - 0931-041X

IS - 6

ER -